Staphylococcus via an interaction with the ELR+ CXC chemokine ENA-78 is associated with BOS

Am J Transplant. 2015 Mar;15(3):792-9. doi: 10.1111/ajt.13029. Epub 2015 Feb 12.

Abstract

Staphylococcus aureus is the most commonly isolated gram-positive bacterium after lung transplantation (LT) and has been associated with poor posttransplant outcomes, but its effect on bronchiolitis obliterans syndrome (BOS) and death in the context of the allograft inflammatory environment has not been studied. A three-state Cox semi-Markovian model was used to determine the influence of allograft S. aureus and the ELR+ CXC chemokines on the survival rates and cause-specific hazards for movement from lung transplant (State 1) to BOS (State 2), from transplant (State 1) to death (State 3), and from BOS (State 2) to death (State 3). Acute rejection, pseudomonas pneumonia, bronchoalveolar lavage fluid (BALF) CXCL5 and its interaction with S. aureus all increased the likelihood of transition from transplant to BOS. Transition to death from transplant was facilitated by pseudomonas infection and single lung transplant. Movement from BOS to death was affected by the interaction between aspergillus, pseudomonas and CXCL5, but not S. aureus. S. aureus isolation had state specific effects after LT and only in concert with elevated BALF CXCL5 concentrations did it augment the risk of BOS. Pseudomonas and elevated BALF concentrations of CXCL5 continued as significant risk factors for BOS and death after BOS in lung transplantation.

Keywords: Bacterial; bronchiolitis obliterans (BOS); chemokines/chemokine receptors; clinical research; immune regulation; infection and infectious agents; infectious disease; lung transplantation; practice; pulmonology; rejection: chronic; science; translational research.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Bronchiolitis Obliterans / microbiology*
  • Bronchiolitis Obliterans / surgery
  • Bronchoalveolar Lavage Fluid
  • Chemokine CXCL5 / metabolism*
  • Chemokines, CXC / metabolism*
  • Humans
  • Lung Transplantation
  • Staphylococcus aureus / pathogenicity*
  • Treatment Outcome

Substances

  • Chemokine CXCL5
  • Chemokines, CXC